Inside Precision Medicine March 26, 2025
Researchers at the Mayo Clinic Comprehensive Cancer Center have shown that the presence of mutant KRAS (mKRAS) circulating tumor DNA (ctDNA) in plasma and peritoneal fluid is associated with an increased risk for metastases and death in patients with pancreatic ductal adenocarcinoma (PDAC).
Senior study author Mark Truty, MD, hepatobiliary and pancreatic surgical oncologist within Mayo Clinic’s Department of Surgery, said that the findings are “a major advancement for pancreatic ductal adenocarcinoma.”
He explained that although ctDNA blood testing is performed at most major cancer centers on a variety of commercial platforms, the prognostic significance of the findings is often unclear.
“Our data suggests that a positive test indicates a high likelihood of metastatic disease in patients whose imaging does...
Today's Sponsors
Today's Sponsor